 | 
| ||
| home > Wockhardt > news | |||
| Wockhardt’s Q3 Results 2009 | |||
| 31 Oct 2009
, Mumbai
: Pharmaceutical and biotechnology major Wockhardt Limited today announced a 2.2% growth in consolidated sales revenues to stand at Rs. 923 crore for the third quarter ended September 30, 2009 over the corresponding quarter of 2008. Operating profit (EBIDTA) was Rs. 182 crore. Due to exceptional items, the net loss is Rs. 54 crore. India Business: As per ORG-IMS for Q3-2009, Wockhardt India Branded Business grew by 9%; thereby improving it’s ranking to the 14th position. There were 5 new products launched during this period. Overall 9 brands featured in the list of ‘Top 300’ brands of the industry with 2 brands in the ‘Top 100’. Wockhardt’s Power Brands are showing good consistent growth. Europe Business: Wockhardt UK grew by 17% compared to the industry growth of only 4.5% in Q3-2009. Hospital products in UK grew by 13%, Pharmacy products grew by 16% and exports surged by 73%. 3 new products in Psychotropic, Anti depressant and Iron Supplement were launched. Wockhardt UK’s Contract Manufacturing Organisation (CMO) signed an agreement with scope of work that includes cartridge development and manufacturing. Pinewood Healthcare in Ireland maintains steady sales and Negma Laboratories in France has signed a co-promotion agreement for a diabetic drug and has also executed a CMO agreement in France. Negma’s Nebilox is growing at 15% showing an improvement in market share. USA Business: The US business contributes 20% to Wockhardt’s overall revenues. There were 13 ANDA approvals received till end of September 2009. In the US generic pharmaceutical market, Wockhardt has been consistently growing market shares for all its products. In many instances, Wockhardt, by virtue of being amongst the first-to-file, gains advantages of being an early entrant. Wockhardt currently markets 66 products in the US. About Wockhardt Wockhardt is a technology-driven global pharmaceutical and biotechnology major with an innovative multi-disciplinary research and development programme. It has 5 research centres and 14 world-class manufacturing plants dotting various countries and continents that are compliant to international regulatory standards such as the US FDA, MHRA and other global regulatory bodies. It has end-to-end integrated capabilities for its products, starting with manufacture of the oral and sterile API’s, the dosage forms and marketing through its wholly owned subsidiary in the US. Wockhardt has a global footprint including the US, UK, Ireland and France with a multi-ethnic workforce from 14 different nationalities. |
|||
| | ||
| home > Wockhardt > news | |||
 |
|||
| |||